Could a Half-Dose of aspirin protect elderly hearts just as well?
NCT ID NCT07542860
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at whether a lower daily dose of aspirin (50 mg) is as effective and safer than the standard dose (100 mg) for preventing heart attacks and strokes in Chinese patients aged 60 and older with heart disease. Researchers will follow over 5,400 participants for up to 6 years, tracking major heart events and bleeding complications. The goal is to find the best balance between preventing clots and avoiding bleeding in older adults.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Aspirin (50 mg vs 100 mg daily)
What this could lead to
If successful, this could show that a lower aspirin dose is safer and equally effective for preventing heart attacks and strokes in elderly patients.
What could go wrong
This is an observational extension of an existing study, not a randomized trial, so results may be less definitive. The lower dose might not prevent cardiovascular events as well as the standard dose.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••